ELDN: Eledon Pharmaceuticals Inc. Price to Sales
Eledon Pharmaceuticals is facing a cash shortage due to costly final-stage trials. Nevertheless, the medical community values the company for its breakthrough developments in transplantology. ESG principles and research ethics complement the development strategy. The revenue multiple reflects market expectations, with the indicator reaching , which helps assess the current business valuation.
Analytical breakdowns for Eledon (ELDN)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Capital Eledon Pharmaceuticals|ELDN - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Eledon Pharmaceuticals, Inc|ELDN - Company Debts|Debts to Book Value Eledon|ELDN - Company Long-Term Debt|Company Short-Term Indebtedness Eledon Pharmaceuticals|Intermediate Coverage Ratio eledon.com
- earnings and multiples data:
ELDN - Company Net Income|Forward Earnings Eledon Pharmaceuticals|ELDN - P/E Multiple|Future Price to Earnings Multiple Eledon Pharmaceuticals Inc.|ELDN - PEG Multiple|EV/EBITDA Multiple Eledon|ELDN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Eledon Pharmaceuticals|ELDN - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months eledon.com|ELDN - Earnings growth in current year|Earnings growth forecast for next year Eledon Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:ELDN - eledon.com
To protect capital amid volatility, the investor utilizes the market capitalization-to-annual revenue ratio, which allows for the identification of asset overvaluation relative to actual cash flow. Analyzing the price-to-sales ratio helps assess the business efficiency of Eledon Pharmaceuticals (ELDN), taking into account the costs of environmental laboratory modernization and the implementation of filtration systems within its immunological developments.
Competitors of Eledon Pharmaceuticals
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price to Sales Protagonist Corp|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|KNSA (kiniksa.com) - Price-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|Price to Sales Adaptive Biotech ADPT|P/S Multiple CLDX|Aurinia Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio BioCryst BCRX|veratx.com (VERA) - Price to Sales|DNTH - Price-to-Revenue Ratio|PHVS (Pharvaris NV) - Market Cap to Revenue Ratio|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Precigen, Inc.|pharming.com - Price-to-Sales Ratio|P/S Multiple NKTR|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|P/S Multiple Immunome Bio IMNM|GOSS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|Septerna (SEPN) - Price-to-Revenue Ratio|Market Cap to Revenue Pieris Pharma|SVRA (Savara Corp) - P/S Multiple|P/S Multiple Rigel Corp|P/S Multiple ANAB|Market Cap to Revenue astriatx.com ATXS|P/S Multiple ENGN (enGene)|RAPT Therapeutics Inc. (RAPT) - Price to Sales|JBIO: Market Cap to Revenue|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|TLSA: Market Cap to Sales Volume|CABA (Cabaletta Bio) - P/S Multiple|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|Market Cap to Revenue Avalo Therapeutics Inc AVTX|P/S Multiple AGEN (Agenus)|P/S Multiple climbbio.com CLYM|ZURA - Price-to-Revenue Ratio|ATYR: Price-to-Revenue Ratio|adagene.com (ADAG) - Price-to-Revenue Ratio|IMA - Price-to-Revenue Coefficient|STTK (Shattuck Labs Inc) - P/S Multiple|Price to Sales Equillium Bio EQ|Price-to-Revenue Ratio Connect Biopharma (CNTB)|Price-to-Revenue Ratio IMUX (immunic-therapeutics.com)|P/S Multiple ATRA (Atara Bio)|IFRX: Market Cap to Revenue Ratio|XFOR - Price-to-Revenue Ratio|ACET (Adicet Bio) - Market Cap to Revenue Ratio|celularity.com (CELU) - Price-to-Revenue Ratio|Price-to-Sales Ratio INMB (INmune Bio Inc)|BRNS (Barinthus Bio) - P/S Multiple|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|P/S Multiple akaritx.com (AKTX)|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|Market Capitalization-to-Revenue Ratio QTTB|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|Carisma Therapeutics Inc. (CARM) - P/S Multiple|Market Cap to Revenue XTLB|BOLT: Market Capitalization-to-Revenue Ratio|P/S Multiple HCWB|Price-to-Revenue Coefficient aptevotherapeutics.com|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI - Price-to-Revenue Ratio|XORTX Therapeutics Inc (XRTX) - Market Cap to Revenue|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|P/S Multiple CALI|AFMD - Price to Sales|P/S Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Price to Sales|IGMS - Price-to-Revenue Ratio|ITOS: Price-to-Revenue Ratio|OCEA: P/S Multiple|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|THRD (Third Harmonic Bio, Inc) - P/S Multiple
